Condition

Metastatic Castration-resistant Prostate Cancer

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 158 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials158
Recruiting47
Common interventions25
Lead sponsors shown15
Advertisement

Clinical trials

60 shown
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)NCT07611110 · 2026-05-04
RECRUITING
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate CancerNCT07365995 · 2026-04-22
RECRUITING
Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate CancerNCT07545811 · 2026-04-15
RECRUITING
ACTinium in Castrate-RESistant Prostate Cancer After LUTEtiumNCT07414940 · 2026-04-13
RECRUITING
Supraphysiologic Testosterone Priming Induces Darolutamide Extended ResponseNCT07142551 · 2026-03-09
RECRUITING
Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPCNCT07476001 · 2026-03-03
RECRUITING
Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate CancerNCT07641049 · 2026-03-02
RECRUITING
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid TumorsNCT07288359 · 2025-12-29
RECRUITING
A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)NCT07244341 · 2025-12-03
RECRUITING
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerNCT07213674 · 2025-11-28
RECRUITING
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)NCT07103018 · 2025-11-21
RECRUITING
A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate CancerNCT07189403 · 2025-11-04
RECRUITING
The COSMYC Trial (COmbined Suppression of MYC)NCT06922318 · 2025-08-19
RECRUITING
Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate CancerNCT06738303 · 2025-07-14
RECRUITING
A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate CancerNCT06533644 · 2025-05-29
RECRUITING
Post Marketing Study on Pluvicto in KoreaNCT06514521 · 2025-04-18
RECRUITING
Study of Re-treatment With [177Lu]Lu-PSMA in Men With Metastatic Castration Resistance Prostate CancerNCT06866938 · 2025-04-11
RECRUITING
Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response GenesNCT06439225 · 2024-12-30
RECRUITING
XL092 in Patients With Metastatic Castration-Resistant Prostate CancerNCT06568562 · 2024-12-09
RECRUITING
Radiotherapy Combined With Fluzopanib and Abiraterone Acetate Tablets (II) Treatment for mCRPCNCT06971211 · 2024-11-27
RECRUITING
Intestinal Akkermansia Muciniphila in Prostate CancerNCT06242509 · 2024-11-20
RECRUITING
Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate CancerNCT06228053 · 2024-11-18
RECRUITING
Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPCNCT06193486 · 2024-10-26
RECRUITING
Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)NCT06401980 · 2024-10-22
RECRUITING
Study With [225Ac]Ac-FL-020 in mCRPC ParticipantsNCT06492122 · 2024-08-30
RECRUITING
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)NCT06520345 · 2024-07-26
RECRUITING
Efficacy and Safety of Organoid-Based Drug Sensitivity Screening to Guide the Treatment of mCRPC Patients Progressed After First-line TreatmentNCT06529549 · 2024-07-24
RECRUITING
Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate CancerNCT06480110 · 2024-06-20
RECRUITING
Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide TetraxetanNCT06099093 · 2024-04-01
RECRUITING
PROCARE - PROstate Cancer Real World Evidence RegistryNCT06835218 · 2024-01-29
RECRUITING
A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC PatientsNCT06155084 · 2023-12-26
RECRUITING
Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPCNCT06100705 · 2023-12-20
RECRUITING
Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate CancerNCT05766371 · 2023-12-15
RECRUITING
Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPCNCT05762536 · 2023-11-29
RECRUITING
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate CancerNCT06067841 · 2023-10-18
RECRUITING
Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate CancerNCT05613894 · 2023-07-14
RECRUITING
64Cu-GRIP B in Patients With Advanced MalignanciesNCT05888532 · 2023-05-25
RECRUITING
FOG-001 in Locally Advanced or Metastatic Solid TumorsNCT05919264 · 2023-05-23
RECRUITING
Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).NCT05720130 · 2023-03-15
RECRUITING
177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate CancerNCT05603559 · 2023-01-01
RECRUITING
EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&TNCT05521412 · 2022-09-29
RECRUITING
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)NCT05519449 · 2022-09-15
RECRUITING
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)NCT05489211 · 2022-09-06
RECRUITING
Anti-tumour Activity of (177Lu) rhPSMA-10.1 InjectionNCT05413850 · 2022-07-20
RECRUITING
Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate CancerNCT05113537 · 2022-07-08
RECRUITING
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate CancerNCT05125016 · 2021-11-30
RECRUITING
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasNCT04104776 · 2019-09-18
RECRUITING
Phase II Trial of Zanzalitinib in Patients With Metastatic Castration Resistant Prostate CancerNCT07608718 · 2026-10-01
NOT_YET_RECRUITING
Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical TherapyNCT07609225 · 2026-10-01
NOT_YET_RECRUITING
A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard TherapyNCT07423117 · 2026-02-06
NOT_YET_RECRUITING
Clinical Trial to Evaluate the Tolerance of TQB3201 TabletsNCT07172126 · 2025-09-01
NOT_YET_RECRUITING
Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPCNCT06895811 · 2025-03-27
ACTIVE_NOT_RECRUITING
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate CancerNCT06764485 · 2025-03-13
ACTIVE_NOT_RECRUITING
FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)NCT06909825 · 2025-02-26
ACTIVE_NOT_RECRUITING
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)NCT06691984 · 2024-12-09
ACTIVE_NOT_RECRUITING
A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate CancerNCT07553988 · 2024-10-24
ACTIVE_NOT_RECRUITING
177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate CancerNCT06329830 · 2024-10-01
WITHDRAWN
LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate CancerNCT06303713 · 2024-05-22
ACTIVE_NOT_RECRUITING
A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPCNCT06383052 · 2024-04-26
ACTIVE_NOT_RECRUITING
[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate CancerNCT06229366 · 2024-04-03
ACTIVE_NOT_RECRUITING

Common interventions

Trial status mix

RECRUITING47
COMPLETED31
ACTIVE_NOT_RECRUITING30
TERMINATED23
UNKNOWN19
NOT_YET_RECRUITING4
WITHDRAWN2
APPROVED_FOR_MARKETING1
ENROLLING_BY_INVITATION1

Phase mix

PHASE177
PHASE275
PHASE316
EARLY_PHASE17
NA3
PHASE42
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.